Defence minister Rajnath Singh on Monday released the first batch of the 2-deoxy-D-glucose (2-DG) drug developed by the Defence Research and Development Organisation (DRDO) for treatment of Covid-19.
The anti-COVID therapeutic application of the drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the DRDO, in collaboration with Dr Reddy’s Laboratories (DRL) in Hyderabad.
Handed over the first batch of 2-DG anti Covid drug to the Union Health Minister @drharshvardhan after it was released today.
This 2-DG drug developed by @DRDO_India & DRL is a perfect example of India’s scientific prowess and a milestone in the efforts towards self-reliance. pic.twitter.com/oiuR2VVr2I
— Rajnath Singh (@rajnathsingh) May 17, 2021
Speaking on the occasion, the Defence Minister congratulated DRDO and DRL, Hyderabad for manufacturing the drug that will help the COVID patients to reduce oxygen dependency and recover quickly.
“The drug is a perfect example of the country’s scientific prowess and a milestone in the efforts towards self-reliance,” reads a statement issued by the Ministry of Defence.
“2-DG drug is a new ray of hope in these challenging times,” said Rajnath Singh, expressing confidence that the medicine will play a crucial role in winning the fight against COVID-19.
The drug comes in powder form in a sachet and is taken orally by dissolving it in water, the ministry said.
